Gene · 57721
NIH grants1,078
NIH grants whose papers are about the gene, through NIH's grant-paper links.
501 to 520 of 1,078
Download this page as JSON| Grant | Title | METTL14 papers | Newest fiscal year |
|---|---|---|---|
| R01AI069000 | Roles for microRNA-122 and circular RNAs in flavivirus RNA amplification | 1 | 2022 |
| R01AI134058 | Modeling of HIF-1-alpha Regulation of B Cell Migration | 1 | 2022 |
| R01AR064195 | Genetic regulation of progenitor cells in appendicular skeletal development | 1 | 2022 |
| R01CA203849 | Mechanism and role of aberrant AR activity in castration-resistant prostate cancer | 1 | 2022 |
| R01CA217820 | Co-targeting mTOR and YAP signaling in glioblastoma | 1 | 2022 |
| R01CA217923 | SESN2 and therapeutic effect of Isohapontigenin (ISO) | 1 | 2022 |
| R01CA222007 | miR-155 targeted therapeutics for precision medicine in lung cancer | 1 | 2022 |
| R01CA224275 | Targeting Lipid Unsaturation in Ovarian Cancer Stem Cells | 1 | 2022 |
| R01CA225231 | Identification of therapeutic targets for leukemia stem cells in AML-iPSC models | 1 | 2022 |
| R01CA227001 | A SIGNALING PATHWAY SPECIFIC FOR ALKYLATION DAMAGE | 1 | 2022 |
| R01CA230854 | (PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer | 1 | 2022 |
| R01CA232347 | Targeting a Treg deubiquitinase in antitumor immune therapy | 1 | 2022 |
| R01CA232587 | Mechanism of lung cancer resistance to tyrosine kinase inhibitor and radiation treatments | 1 | 2022 |
| R01DK119270 | Epitranscriptomic control of erythropoiesis | 1 | 2022 |
| R01DK121997 | The Unfolded Protein Response in Fatty Liver | 1 | 2022 |
| R01ES027845 | Effects of Flame Retardants on Brain Function and Attentional Deficits in School-age Children - Brain Imaging, Neurobehavioral, and Gut Microbiome Studies in a Longitudinal Birth Cohort | 1 | 2022 |
| R01ES029212 | Placental Functional Networks Linking Developmental Pesticide Exposure and Offspring Neurodevelopment | 1 | 2022 |
| R01ES029359 | Epigenetic Stress and Chromate Carcinogenesis | 1 | 2022 |
| R01ES029749 | A Targeted DNA Adductomics Approach for Analyzing > 100 DNA Adducts | 1 | 2022 |
| R01ES032189 | Exposome and Precision Medicine in NAFLD | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/grants?page=26